

## Highlights

- Best Trades of the Week
- Cipla shares gain 2% on final FDA approval for Lanreotide injection
- Supriya Lifescience IPO subscribed 71.51 times on final day, QIB portion booked 31.83 times
- Shriram Properties shares list at 20% discount. What should investors do now?

## ***Shriram Properties shares list at 20% discount.***

### ***What should investors do now?***

Real estate developer Shriram Properties listed its shares at a discount of 20 percent to its issue price, at Rs 94, on the BSE on December 20 in a weak market.

The company's maiden public issue had seen a good response from investors with 4.6 times subscription during December 8-10. The Shriram Group company mopped up Rs 600 crore through the public issue at a price band of Rs 113-118 per equity share.

Catch all the market updates on our blog

While Angel One and Choice Broking had a 'subscribe' rating on the issue, Anand Rathi had advised to 'avoid' noting that the company had been reporting net loss since FY20.

Shriram Properties posted a loss of Rs 60.03 crore on a revenue of Rs 118.17 crore in the six months ended September 2021.

Source:moneycontrol.com

### ***Best Trades of the Week***

13 Dec 2021 Profit of Rs. 141,513

14 Dec 2021 Profit of Rs. 117,014

15 Dec 2021 Profit of Rs. 32,386

16 Dec 2021 Profit of Rs. 56,049

17 Dec 2021 Profit of Rs. 57,227

The market fell sharply to hit nearly two-week low on December 17, as weak global cues amid hawkish stance of major global central banks & rising Omicron cases, along with surprise rate hike by Bank of England dented market sentiment.

The BSE Sensex plunged 889.40 points or 1.54 percent to close at 57,012, while the Nifty50 has breached the crucial 17,000 mark, falling 263 points or 1.53 percent to 16,985.20 and formed a large bearish candle on the daily charts. The index lost 3 percent during the week and saw bearish candle formation on the weekly scale. In this week as well, one of our traders made a profit of Rs. 141,513 on 13 Dec 2021, the highest of all other days in a week. Making a consistent profit should be the ideal approach rather than looking at the percentage of profits. Yogeshwar sir always teach one important rule of the stock market which is "Always work on reducing your risk and never allow yourself to take a big loss."

If you want to stay in the stock market game, then you should work on making a consistent profit and reducing your risk. Risk management is the key to success here. I believe, people who don't follow proper risk management, always find themselves in the struggle. No doubt, you would have made a big profit some days. But the real challenge is to main-

tain that kind of profits everyday day. If you are making Rs. One lack in a day and losing the same on other days. You are not working as a professional trader. I can assume this sort of profit-making is through gambling.

What we have learned at Pathfinders Trainings, you can see the results of that learning by looking at the profits made by professional traders. Every trade is good, even you make less profit. But working on not making big losses in the market should be our priority. If we have the capital to play in the market, our small loss can be turned into a small profit and with consistency, into a big profit.

## Free Stock Market Webinar

Friday (20 December, 2021)  
Register today to attend using the following link:

<https://www.pathfinderstrainings.in/training/freetrainings.aspx>

## Cipla shares gain 2% on final FDA approval for Lanreotide injection

Pharma major Cipla share price rose over 2 percent intraday to Rs 883.90 after its Lanreotide injection got the green light from the US drug watchdog.

“Cipla and its subsidiary Cipla USA, Inc have received the final approval for its Lanreotide injection from the United States Food and Drug Administration (USFDA),” according to a release from the company.

The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs), it added. It is supplied in 60 mg/0.2 ml, 90 mg/0.3 ml, and 120 mg/0.5 ml single-dose pre-filled syringes.

Source:moneycontrol.com

## PATHFINDERS TRAININGS

Let's talk, Don't hesitate to reach out with the contact information below,

### ***Get in Touch***

Pathfinders Trainings

Hiranandani

Thane (West), Mumbai, Maharashtra

400610, India

[service@pathfinderstrainings.in](mailto:service@pathfinderstrainings.in)

M. 9022330008

